About BioNTech Company
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Biotechs Post Record Gains in November Amid Improving Outlook
BioNTech Stock Downgraded, Analyst Reflects Concerns Over Growth and Pipeline Development
J.P. Morgan has downgraded BioNTech SE (NASDAQ:BNTX), acknowledging the company's substantial cash reserves and limited downside potential. The analysts Jessica Fye, Na Sun, and Nick Lenard expressed
European Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday Trading
After starting the trading session in negative territory, European equities traded in the US as American depositary receipts reversed course Friday and were rising 0.16% to 1,240.63 on the S&P Europe
$Shopify(SHOP.US)$ Shares in Shopify rose by 4% in premarket trading after the e-commerce group said its merchants had posted an all-time high of $4.1 billion in combined sales on Black Friday.
Ottawa-based Shopify, which provides software and services to online sellers, said global sales by businesses using the platform had grown by 22% compared to the prior year during the annual post-Thanksgiving ...
$Tesla(TSLA.US)$ stock rose 1.9% after Reuters reported that the electric vehicle manufacturer plans to build a €25,000 (€1 = $1.0753) car at its factory near Berlin, in an attempt to enter the mass market.
$BioNTech(BNTX.US)$ stock rose 3.1% after the drugmaker cut its 2023 revenue target on lower demand for the COVID-19 vaccine made with Pfizer, but said the impact from write-downs at its U.S. partner...